Megalotect

Human Cytomegalovirus Immunoglobulin, the active ingredient in Megalotect, is an immunoglobulin presented as an intravenous solution for intravenous use. It supplies high‑titer neutralizing antibodies that confer passive immunity against human cytomegalovirus (CMV), helping to prevent or mitigate CMV disease in individuals with weakened immune systems, such as organ‑transplant recipients, hematopoietic stem‑cell transplant patients, and other high‑risk groups.

GNH USA supplies Megalotect as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and clinics worldwide.

Megalotect is used to provide passive immunity against human cytomegalovirus in clinical situations where viral replication poses a significant risk. - Solid organ transplant recipients: helps prevent CMV disease following transplantation. - Hematopoietic stem cell transplant patients: aids in treatment of active CMV infection. - CMV‑seronegative recipients of CMV‑positive donor organs: provides prophylaxis to reduce primary infection. - High‑risk immunocompromised patients: supports immune defense against CMV reactivation. - Post‑transplant prophylaxis: reduces incidence of CMV‑related complications.

Megalotect may cause infusion‑related reactions and other adverse events.

Common Side Effects: - Headache: mild to moderate pain during or after infusion. - Fever or chills: transient rise in body temperature. - Nausea: occasional upset stomach. - Fatigue: feeling of tiredness post‑infusion. - Mild hypotension: slight drop in blood pressure during administration. - Injection site erythema: redness at the infusion site.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Acute renal dysfunction: sudden decrease in kidney function. - Thromboembolic events: formation of blood clots. - Aseptic meningitis: inflammation of meninges without infection. - Hemolysis: destruction of red blood cells. - Severe hypotension: marked drop in blood pressure causing dizziness or syncope.

Before using Megalotect, clinicians should consider several safety measures. - Assess CMV serostatus: determine need for prophylaxis or treatment based on donor and recipient serology. - Screen for IgA deficiency: patients with severe IgA deficiency may have increased risk of anaphylaxis. - Monitor renal function: adjust infusion rate or volume in patients with impaired kidneys. - Observe for infusion reactions: be prepared to pause or stop infusion if severe symptoms develop. - Avoid concurrent nephrotoxic drugs: reduce additional risk to kidney health. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Megalotect can interact with other medications, requiring careful management.

Major Interactions (Avoid): - Concurrent high‑dose immunoglobulins: may increase serum viscosity and risk of hyperviscosity syndrome. - Live vaccines: immunoglobulin may diminish vaccine efficacy, so timing should be coordinated.

Moderate Interactions (Monitor Closely): - Nephrotoxic agents (e.g., aminoglycosides, amphotericin B): may exacerbate renal side effects. - Anticoagulants (e.g., warfarin): immunoglobulin can affect coagulation parameters. - ACE inhibitors or ARBs: combined use may increase risk of renal impairment.